Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HibTITER + DPT-IPV
- Development stage
- Discontinued
- Lead developer
- Nuron Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
HibTITER + DPT-IPV is a pentavalent pediatric vaccine combination evaluated by Mitsubishi Tanabe Pharma Corporation for the prevention of multiple infectious diseases in infants. The regimen consists of MT-2301 (HibTITER), a conjugate vaccine where the Haemophilus influenzae type b (Hib) capsular polysaccharide (polyribosylribitol phosphate, PRP) is covalently linked to the CRM197 carrier protein (a non-toxic mutant of diphtheria toxin), co-administered with a DPT-IPV vaccine (targeting diphtheria, pertussis, tetanus, and inactivated polio). This combination acts as an immunostimulant to induce protective antibody levels against five major pathogens. Although HibTITER was licensed from Nuron Biotech for the Japanese market, development of this specific co-administration protocol in Japan was discontinued in February 2017.
- Brand names
- HibTITER
- Other names
- Haemophilus b conjugate vaccine (Diphtheria CRM197 Protein Conjugate) + DPT-IPVHaemophilus influenzae type b conjugate vaccine + DPT-IPV
02
Targets
Diphtheria toxinHib conjugate (Haemophilus influenzae type b capsular polysaccharide-protein conjugate)
Beyond the preview
Go deeper on HibTITER + DPT-IPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HibTITER + DPT-IPV.